COST-EFFECTIVENESS EVALUATION OF THE USE OF CAPECITABINE plus DOCETAXEL VS GEMCITABINE plus DOCETAXEL IN PATIENTS WITH RECURRENT BREAST CANCER WHO PREVIOUSLY FAILED TO ANTHRACYCLINE CHEMOTHERAPY AND/OR WITH METASTATIC DISEASE

被引：0
|
作者：
Tenorio, C. [1 ]
Vargas, J. [2 ]
Martinez, J. [3 ]
机构：
[1] Inst Nacl Cancerol, Mexico City, DF, Mexico
[2] Econopharma Consulting SA CV, Mexico City, DF, Mexico
[3] Econopharma, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74330-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A271 / A271
页数：1
相关论文
共 50 条
  • [1] Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
    Chan, Stephen
    Romieu, Gilles
    Huober, Jens
    Delozier, Thierry
    Tubiana-Hulin, Michele
    Schneeweiss, Andreas
    Lluch, Ana
    Llombart, Antonio
    du Bois, Andreas
    Kreienberg, Rolf
    Mayordomo, Jose Ignacio
    Anton, Antonio
    Harrison, Mark
    Jones, Alison
    Carrasco, Eva
    Vaury, A. Thareau
    Frimodt-Moller, Bente
    Fumoleau, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) : 1753 - 1760
  • [2] A Pooled Analysis of Gemcitabine Plus Docetaxel Versus Capecitabine Plus Docetaxel in Metastatic Breast Cancer
    Seidman, Andrew D.
    Chan, Stephen
    Wang, Jin
    Zhu, Chao
    Xu, Cong
    Xu, Binghe
    ONCOLOGIST, 2014, 19 (05): : 443 - 452
  • [3] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
  • [4] Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer
    Saeki T.
    Takashima S.
    Breast Cancer, 2004, 11 (2) : 116 - 120
  • [5] Gemcitabine plus docetaxel versus capecitabine plus docetaxel for patients with anthracycline-pretreated metastatic breast cancer: a review of the results of a European Phase III trial
    Chan, S
    EJC SUPPLEMENTS, 2005, 3 (05): : 17 - 21
  • [6] A phase III trial of Gemcitabine plus Docetaxel (GD) versus Capecitabine plus Docetaxel (CD) for patients (pt) with anthracycline-pretreated metastatic breast cancer
    Chan, S.
    Sharma, R.
    Romieu, G.
    Huober, T.
    Delozier, T.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, A.
    Fumoleau, P.
    EJC SUPPLEMENTS, 2007, 5 (03): : 15 - 16
  • [7] Capecitabine plus docetaxel combination therapy -: Cost-effectiveness in patients with anthracycline-pretreated advanced breast carcinoma
    Verma, S
    Maraninchi, D
    O'Shaughnessy, J
    Jamieson, C
    Jones, S
    Martín, M
    McKendrick, J
    Miles, D
    Twelves, C
    Hornberger, J
    CANCER, 2005, 103 (12) : 2455 - 2465
  • [8] Impact of symptoms and toxicity on quality of life: Exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer.
    Fumoleau, P.
    Romieu, G.
    Chan, S.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Bougnoux, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 48S - 48S
  • [9] Docetaxel plus capecitabine in the treatment of previous anthracycline-treated patients with metastatic breast cancer
    Bensalem, A.
    Bouzid, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
    Levy, C
    Fumoleau, P
    CANCER TREATMENT REVIEWS, 2005, 31 : S17 - S22
12345